^
Association details:
| Biomarker: | CCL5 elevation |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + Cotellic (cobimetinib) (MEK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer
Published date:
10/03/2022
Excerpt:
We examined immune features in peripheral blood from 77 patients with advanced BTC enrolled in a phase II clinical trial investigating atezolizumab with or without cobimetinib….Higher baseline levels of IL23 and RANTES corresponded to improved clinical outcomes following combination treatment....This work represents a comprehensive analysis of peripheral immune features in patients with BTC and systemic responses to dual MEK/PD-L1 inhibition.
DOI:
10.1158/1078-0432.CCR-22-1123
